 HAYWARD, Calif.--BUSINESS WIRE--Arcus Biosciences, Inc. NYSE:RCUS, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Companys Board of Directors granted thirteen new employees options to purchase a total of 140,000 shares of the Companys common stock at an exercise price per share of 35.77, which was the closing price on April 23, 2021. The stock options were granted pursuant to the Compa 